TG Therapeutics, Inc. (TGTX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
57.07
↓-38% vs avg
5yr avg: 92.60
30Y Low40.4·High40.4
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
10.72
↓-35% vs avg
5yr avg: 16.57
30Y Low0.2·High27.3
ROE
↑
102.8%
↓+540% vs avg
5yr avg: -23.4%
30Y Low-381%·High103%
Debt/EBITDA
↓
2.11
↓-53% vs avg
5yr avg: 4.46
30Y Low2.1·High6.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TGTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
TG Therapeutics, Inc. trades at 15.5x earnings, 89% below its 5-year average of 137.2x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 30%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.9B | $4.8B | $4.8B | $2.5B | $1.6B | $2.5B | $6.0B | $981M | $309M | $509M | $228M |
| Enterprise Value | $7.1B | $5.0B | $4.9B | $2.6B | $1.6B | $2.3B | $5.5B | $909M | $268M | $452M | $203M |
| P/E Ratio → | 15.53 | 10.76 | 200.67 | 200.23 | — | — | — | — | — | — | — |
| P/S Ratio | 11.15 | 7.81 | 14.67 | 10.86 | 575.19 | 375.58 | 39471.44 | 6453.25 | 2035.62 | 3340.12 | 1496.53 |
| P/B Ratio | 10.72 | 7.43 | 21.70 | 15.80 | 27.34 | 10.59 | 11.55 | 25.40 | 12.87 | 7.60 | 6.36 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TGTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
TG Therapeutics, Inc.'s enterprise value stands at 57.1x EBITDA, 38% below its 5-year average of 92.6x. The Healthcare sector median is 14.4x, placing the stock at a 297% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.10 | 14.89 | 10.93 | 568.28 | 342.71 | 36106.55 | 5980.67 | 1760.02 | 2968.74 | 1332.71 |
| EV / EBITDA | 57.07 | 40.41 | 116.09 | 121.31 | — | — | — | — | — | — | — |
| EV / EBIT | 57.18 | 37.23 | 98.75 | 99.48 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TGTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
TG Therapeutics, Inc. earns an operating margin of 20.0%. Operating margins have expanded from 8.8% to 20.0% over the past 3 years, signaling improving operational efficiency. Return on equity of 102.8% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 16.4% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.6% | 83.6% | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% | 100.0% | 42.1% | 46.0% | 58.7% |
| Operating Margin | 20.0% | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | -179996.1% | -111220.4% | -114736.8% | -77904.6% | -51823.5% |
| Net Profit Margin | 72.6% | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183803.3% | -113730.9% | -114132.9% | -77749.9% | -51353.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 102.8% | 102.8% | 12.2% | 11.6% | -151.4% | -92.0% | -100.1% | -551.9% | -381.2% | -230.4% | -113.9% |
| ROA | 54.5% | 54.5% | 5.2% | 4.8% | -78.1% | -69.3% | -70.8% | -140.2% | -191.7% | -155.7% | -93.0% |
| ROIC | 16.4% | 16.4% | 13.3% | 14.2% | -578.0% | -2052.2% | — | — | — | -835.7% | -205.5% |
| ROCE | 17.7% | 17.7% | 11.0% | 9.9% | -96.0% | -80.9% | -88.7% | -274.2% | -305.5% | -221.2% | -112.1% |
TGTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
TG Therapeutics, Inc. carries a Debt/EBITDA ratio of 2.1x, which is manageable (36% below the sector average of 3.3x). Net debt stands at $182M ($261M total debt minus $79M cash). Interest coverage of 5.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.40 | 0.40 | 1.14 | 0.69 | 1.42 | 0.33 | 0.08 | 1.06 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 2.11 | 2.11 | 6.01 | 5.26 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.28 | 0.33 | 0.11 | -0.33 | -0.93 | -0.98 | -1.86 | -1.74 | -0.84 | -0.70 |
| Net Debt / EBITDA | 1.47 | 1.47 | 1.75 | 0.85 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 5.02 | 5.02 | 2.07 | 2.04 | -20.96 | -60.74 | -43.14 | -31.70 | -99.54 | -103.23 | — |
TGTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
TG Therapeutics, Inc.'s current ratio of 4.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.29x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.92x to 4.10x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.10 | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 |
| Quick Ratio | 3.29 | 3.29 | 5.03 | 5.18 | 3.16 | 5.06 | 6.99 | 1.77 | 1.78 | 3.05 | 2.68 |
| Cash Ratio | 0.92 | 0.92 | 3.43 | 4.05 | 3.04 | 4.81 | 6.91 | 1.66 | 1.77 | 3.03 | 2.66 |
| Asset Turnover | — | 0.58 | 0.57 | 0.71 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.80 | 0.80 | 0.35 | 0.35 | — | — | — | — | 0.01 | 0.01 | 0.01 |
| Days Sales Outstanding | — | 181.01 | 143.32 | 79.81 | — | 75.79 | — | — | 228.13 | 259.81 | 200.85 |
TGTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
TG Therapeutics, Inc. returns 1.3% to shareholders annually primarily through share buybacks. The earnings yield of 6.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.4% | 9.3% | 0.5% | 0.5% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 1.3% | 1.9% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.3% | 1.9% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $161M | $160M | $149M | $135M | $132M | $115M | $88M | $75M | $62M | $49M |
Peer Comparison
Compare TGTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TGTXYou | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 VRTX | $108B | 27.7 | 21.5 | 33.8 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 INCY | $20B | 15.3 | 11.5 | 14.4 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TGTX vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonTGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
What is TG Therapeutics, Inc.'s P/E ratio?
TG Therapeutics, Inc.'s current P/E ratio is 15.5x. The historical average is 7.0x. This places it at the 100th percentile of its historical range.
What is TG Therapeutics, Inc.'s EV/EBITDA?
TG Therapeutics, Inc.'s current EV/EBITDA is 57.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 40.4x.
What is TG Therapeutics, Inc.'s ROE?
TG Therapeutics, Inc.'s return on equity (ROE) is 102.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -128.0%.
Is TGTX stock overvalued?
Based on historical data, TG Therapeutics, Inc. is trading at a P/E of 15.5x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are TG Therapeutics, Inc.'s profit margins?
TG Therapeutics, Inc. has 83.6% gross margin and 20.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does TG Therapeutics, Inc. have?
TG Therapeutics, Inc.'s Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.